Guggenheim raised the firm’s price target on AtaiBeckley (ATAI) to $16 from $11 and keeps a Buy rating on the shares. The firm’s recent meetings with management reinforced its “conviction” in the BPL-003 program heading into Phase 3 initiation this quarter, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Buy Rating on Atai Beckley N.V. Driven by Differentiated Psychedelic TRD Program and Favorable Risk‑Reward Profile
- Trump to sign order on psychedelic used for PTSD, CBS News says
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results
- AtaiBeckley announces peer-reviewed Phase 2a results of BPL-003 study
- Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial